REG - Creo Medical Group - Grant of Options

Creo MedicalAnnouncement

26/03/2025 07:15

For best results when printing this announcement, please click on link below:
https://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20250326:nRSZ1500Ca&default-theme=true

RNS Number : 1500C  Creo Medical Group PLC  26 March 2025

Creo Medical Group plc

("Creo", the "Company" or the "Group")

 

Grant of Options

 

Creo Medical Group plc (AIM: CREO), a medical device company focused on the
emerging field of minimally invasive surgical endoscopy for pre-cancer and
cancer patients, announces that on 24 March 2025, it granted options over an
aggregate 6,474,713 ordinary shares of £0.001 in the Company (the "Options")
to certain Directors of the Company as follows:

 

 Name of Director     Share Options Granted  Exercise Price  Total no. of options over ordinary shares now held

 Craig Gulliford      2,062,500              £0.13125        9,970,001
 Christopher Hancock  1,384,063              £0.13125        7,832,637
 Richard Rees         1,410,938              £0.13125        6,066,870
 David Woods          1,617,212              £0.13125        3,712,322

 

Vesting of the options is subject to performance conditions through to
December 2027.

 

For further information please contact:

 

 Creo Medical Group plc                                                        www.creomedical.com
                                                                               (https://protect.checkpoint.com/v2/___http:/www.creomedical.com/___.YzJ1OmludHVpdGl2ZTpjOm86NWJlYzBmMzJjY2MyZTBiZWFkNmJkZmVmNzdhM2MwMTI6NjoyYWU4OjczNzQyNWUwODBjYTEwNzAxYWMzNWEyZDQ3YzI1ZmEwYWMzYTc4M2Q2M2NjYzEyNTQwZWM3ODc4NTk3NTE4YTQ6cDpUOk4)
 Richard Craven, Company Secretary                                             Via Walbrook PR

 Deutsche Numis (Nominated Adviser, sole Broker and Financial Adviser)         +44 (0)20 7260 1000

 Freddie Barnfield / Duncan Monteith / Euan Brown / Sher Shah

 Walbrook PR Ltd                      Tel: +44 (0)20 7933 8780 or creo@walbrookpr.com (mailto:creo@walbrookpr.com)
 Paul McManus / Alice Woodings        Mob: +44 (0)7980 541 893 / +44 (0)7407 804 654

 Phillip Marriage                     Mob: +44 (0)7867 984 082

 

 

About Creo Medical

Creo is a medical device company focused on the development and
commercialisation of minimally invasive electrosurgical devices, bringing
advanced energy to endoscopy.

 

The Company's vision is to improve patient outcomes through the development
and commercialisation of a suite of electrosurgical medical devices, each
enabled by CROMA, powered by Kamaptive. The Group has developed the CROMA
powered by Kamaptive full-spectrum adaptive technology to optimise surgical
capability and patient outcomes. Kamaptive is a seamless, intuitive
integration of multi-modal energy sources, optimised to dynamically adapt to
patient tissue during procedures such as resection, dissection, coagulation,
and ablation of tissue. Kamaptive technology provides clinicians with
increased flexibility, precision and controlled surgical solutions. CROMA
currently delivers bipolar radiofrequency ("RF") energy for precise localised
cutting and focused high frequency microwave ("MW") energy for controlled
coagulation and ablation via a single accessory port. This technology,
combined with the Group's range of patented electrosurgical devices, is
designed to provide clinicians with flexible, accurate and controlled clinical
solutions. The Directors believe the Company's technology can impact the
landscape of surgery and endoscopy by providing a safer, less invasive and
more cost-efficient option for procedures.

 

For more information, please refer to the website www.creomedical.com
(https://protect.checkpoint.com/v2/___http:/www.creomedical.com/___.YzJ1OmludHVpdGl2ZTpjOm86NWJlYzBmMzJjY2MyZTBiZWFkNmJkZmVmNzdhM2MwMTI6NjoyYWU4OjczNzQyNWUwODBjYTEwNzAxYWMzNWEyZDQ3YzI1ZmEwYWMzYTc4M2Q2M2NjYzEyNTQwZWM3ODc4NTk3NTE4YTQ6cDpUOk4)

 

 

Notification and public disclosure of transactions by persons discharging
managerial responsibilities and persons closely associated with them:

 

 1    Details of the person discharging managerial responsibilities / person closely

    associated

 a)   Name                                                         Craig Gulliford

 2    Reason for the notification

 a)   Position/status                                              Chief Executive Officer

 b)   Initial notification /Amendment                              Initial notification

 3    Details of the issuer, emission allowance market participant, auction

    platform, auctioneer or auction monitor

 a)   Name                                                         Creo Medical Group plc

 b)   LEI                                                          213800H188ZDCWWXFA21

 4    Details of the transaction(s): section to be repeated for (i) each type of

    instrument; (ii) each type of transaction; (iii) each date; and (iv) each
      place where transactions have been conducted

 a)   Description of the financial instrument, type of instrument  Ordinary shares of £0.001 each

      Identification code                                          GB00BZ1BLL44

 b)   Nature of the transaction                                    Grant of Options

 c)   Price(s) and volume(s)

                                                                                     Price(s)          Volume(s)
                                                                                     Nil               2,062,500

 d)   Aggregated information

      - Aggregated volume                                          N/A - single transaction

      - Price

 e)   Date of the transaction                                      24 March 2025

 f)   Place of the transaction                                     Off-market

 

 1    Details of the person discharging managerial responsibilities / person closely

    associated

 a)   Name                                                         Chris Hancock

 2    Reason for the notification

 a)   Position/status                                              Chief Technology Officer

 b)   Initial notification /Amendment                              Initial notification

 3    Details of the issuer, emission allowance market participant, auction

    platform, auctioneer or auction monitor

 a)   Name                                                         Creo Medical Group plc

 b)   LEI                                                          213800H188ZDCWWXFA21

 4    Details of the transaction(s): section to be repeated for (i) each type of

    instrument; (ii) each type of transaction; (iii) each date; and (iv) each
      place where transactions have been conducted

 a)   Description of the financial instrument, type of instrument  Ordinary shares of £0.001 each

      Identification code                                          GB00BZ1BLL44

 b)   Nature of the transaction                                    Grant of Options

 c)   Price(s) and volume(s)

Price(s)  Volume(s)
                                                                   Nil       1,384,063

 

 d)   Aggregated information

      - Aggregated volume                                          N/A - single transaction

 e)   Date of the transaction                                      24 March 2025

 f)   Place of the transaction                                     Off-market

 

 

d)

 

Aggregated information

- Aggregated volume

N/A - single transaction

e)

 

Date of the transaction

 

 

24 March 2025

f)

 

Place of the transaction

 

 

Off-market

 

 

 1    Details of the person discharging managerial responsibilities / person closely

    associated

 a)   Name                                                         Richard Rees

 2    Reason for the notification

 a)   Position/status                                              Chief Financial Officer

 b)   Initial notification /Amendment                              Initial notification

 3    Details of the issuer, emission allowance market participant, auction

    platform, auctioneer or auction monitor

 a)   Name                                                         Creo Medical Group plc

 b)   LEI                                                          213800H188ZDCWWXFA21

 4    Details of the transaction(s): section to be repeated for (i) each type of

    instrument; (ii) each type of transaction; (iii) each date; and (iv) each
      place where transactions have been conducted

 a)   Description of the financial instrument, type of instrument  Ordinary shares of £0.001 each

      Identification code                                          GB00BZ1BLL44

 b)   Nature of the transaction                                    Grant of Options

 c)   Price(s) and volume(s)

Price(s)  Volume(s)
                                                                   Nil       1,410,938

 

 d)   Aggregated information

      - Aggregated volume                                          N/A - single transaction

 e)   Date of the transaction                                      24 March 2025

 f)   Place of the transaction                                     Off-market

 

 

d)

 

Aggregated information

- Aggregated volume

N/A - single transaction

e)

 

Date of the transaction

 

 

24 March 2025

f)

 

Place of the transaction

 

 

Off-market

 

 

 

 1    Details of the person discharging managerial responsibilities / person closely

    associated

 a)   Name                                                         David Woods

 2    Reason for the notification

 a)   Position/status                                              Chief Commercial Officer

 b)   Initial notification /Amendment                              Initial notification

 3    Details of the issuer, emission allowance market participant, auction

    platform, auctioneer or auction monitor

 a)   Name                                                         Creo Medical Group plc

 b)   LEI                                                          213800H188ZDCWWXFA21

 4    Details of the transaction(s): section to be repeated for (i) each type of

    instrument; (ii) each type of transaction; (iii) each date; and (iv) each
      place where transactions have been conducted

 a)   Description of the financial instrument, type of instrument  Ordinary shares of £0.001 each

      Identification code                                          GB00BZ1BLL44

 b)   Nature of the transaction                                    Grant of Options

 c)   Price(s) and volume(s)

Price(s)  Volume(s)
                                                                   Nil       1,617,212

 

 d)   Aggregated information

      - Aggregated volume                                          N/A - single transaction

 e)   Date of the transaction                                      24 March 2025

 f)   Place of the transaction                                     Off market

 

 

d)

 

Aggregated information

- Aggregated volume

N/A - single transaction

e)

 

Date of the transaction

 

 

24 March 2025

f)

 

Place of the transaction

 

 

Off market

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  DSHFFFFFVRIEFIE